LOBEF / Lobe Sciences secures $1.3M private placement to fund advancement of its brain trauma-treating psilocin analogs

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced Mathew Lee as its new Chief Financial Officer. Lee is the president of Manning Lee Management more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) told investors that it signed an amendment to its April 18, 2023, share purchase agreement to acquire Altemi more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has provided further details regarding its acquisition of Altemia & Company LLC, first announced on April 1 more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has commenced a Phase 1 clinical study to evaluate L-130, their proprietary stabilized psilocin anal more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) eff more_horizontal

Lobe Sciences said it has entered into a commercial distribution agreement with Pentec Health for Altemia, a medical food with Lobe's proprietary form more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) stock shot up Tuesday after the biopharma company said it had inked a share purchase agreement to acquire Al more_horizontal

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) revealed that it has inked a share purchase agreement to acquire Altemia & Company LLC and all its assets, i more_horizontal